CA2341036A1 - Cyclic ester or amide derivatives - Google Patents

Cyclic ester or amide derivatives Download PDF

Info

Publication number
CA2341036A1
CA2341036A1 CA002341036A CA2341036A CA2341036A1 CA 2341036 A1 CA2341036 A1 CA 2341036A1 CA 002341036 A CA002341036 A CA 002341036A CA 2341036 A CA2341036 A CA 2341036A CA 2341036 A1 CA2341036 A1 CA 2341036A1
Authority
CA
Canada
Prior art keywords
compound
independently
substituted
heteroatom
cycloalkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002341036A
Other languages
French (fr)
Inventor
David C. Limburg
Gregory S. Hamilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GPI Nil Holdings Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2341036A1 publication Critical patent/CA2341036A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

This invention relates to low molecular weight, small molecule cyclic esters and amides having an affinity for FKBP-type immunophilins, pharmaceutical compositions comprising the same, and methods of using the same to effect a neuronal activity.

Description

CYCLIC ESTER OR AMIDE DERIVATI S
SACRGROUND OF THE INVENTION
5 Field of Invention This invention relates to neurotrophic low molecular weight, small molecule cyclic ester or amide derivatives having an affinity for FKBP-type immunophii:i.ns, pharmaceutical compositions comprising 10 the same, and methods of using the same to effect a neuronal acaivity.
Description of Related Art The term immunophilin refers to a number of proteins that serve as receptors for the principal 15 immunosuppressant drugs, cyclosporin A ~CsA), FK506, and rapamycin. Known classes of immunophilins are cyclophiiins and FK506 binding proteins, or FKBPS.
Cyclosporin A binds to cyclophilin A, while FK506 and rapamycin bind to FKHP12. These immunoph.ilin-drug 20 complexes interface with various intracellular signal transducti.on systems, especially in the immune and nervous systems .
Immunophilins are known to have peptidyl -prolyl isomerase (i?PIase), or rotamase, enzyme activity. It 25 has been dsstermined that rotamase enzyme activity plays a iole in the catalyzation of the interconver~~ion of the cis and 4rans isomers of peptide and protein substrates for the immunophilin proteins.
Immunophilins were originally discovered and studied in t:he immune tissue. It was initially 5 postulated by those skilled in the art that inhibition of the immunophilins' rotamase activity leads to inhibition of- T-cell proliferation, thereby causing the immunosuppressive activity exhibited by immunosuppressant drugs, such as cyclosporin A, FK506, 10 and rapamycin., Further study has shown that the inhibition of rotamase activity, in and of itself, does not result in immunosuppressive activity.
Schreiber et al., Science, 1990, vol. 250, pp. 556-559. Instead,, immunosuppression appears to stem from 15 the formation of a complex of immunosuppressant drugs with immunophilins. It has been shown that the immunophilin-drug complexes interact with ternary protein targets as their mode of action. Schreiber et al., Cell, 1991, vol. 66, pp. 807-815. In the case of 20 FKBP-FK506 and cyclophilin-CsA, the immunophilin-drug complex binds to the enzyme calcineurin and inhibits the T-cell receptor signaling necessary to T-cell proliferation. Similarly, the immunophilin-drug complex of FKBP-rapamycin interacts with the 25 RAFT1/FRAP protein and inhibits the IL-2 receptor WO 00/17161 PCTlUS99/21290 signaling also necessary to T-cell proliferation. In either case, T-cell proliferation is inhibited.
In addition to immune tissues, immunophilins have also been found in the central nervous system.
5 Immunophil.in concentrations are 10-50 times greater in the central nervous system than in the immune system.
Within neural tissues, immunophilins appear to influencE nitric oxide synthesis, neurotransmitter release, and neuronal process extension.
10 It ria,s been found that picomolar concentrations of immunosuppressants such as FK506 and rapamycin stimulate neurite outgrowth in PC12 cells and sensory neurons ouch as dorsal root ganglion cells (DRGs).
Lyons et al., Proc. of Natl. Acad. Sci., 1994, vol.
15 91, pp. 3191-3195. In whole animal experiments, FK506 has been shown to stimulate nerve regeneration following :Facial nerve injury.
However, when administered chronically;
immunosupp:ressant drugs exhibit a number of 20 potentially serious side effects including nephrotoxicity, such as impairment of glomerular filtration and irreversible interstitial fibrosis (Kopp et a 1., J. Am. Soc. Nephrol., 1991, 1:162);
neurological deficits, such as involuntary tremors, or 25 non-speci.f:ic cerebral angina, such as non-localized headaches (De Groen et al., N. Engl. J. Med., 1987, 317:861); anal vascular hypertension with complications resulting therefrom (Kahan et al., N. Engl. J. Med., 1989, 321: 1'725) .
Surprisingly, it has been found that certain 5 compounds with a high affinity for FKBPs are potent rotamase inhibitors and exhibit excellent neurotrophic effects, bui~ are devoid of immunosuppressive activity.
These findings suggest the use of rotamase inhibitors in treating various peripheral neuropathies and 10 enhancing neuronal regrowth in the central nervous system (CNS).
Studies have demonstrated that neurodegenerative disorders, such as Alzheimer's disease, Qarkinson's disease anct amyotrophic lateral sclerosis (ALS), may 15 occur due t:o the loss, or .decreased availability, of a neurotrophic substance specific for a particular population of neurons affected in the disorder.
Several neurotrophic factors affecting' specific neuronal populations in the central nervous system 20 have been identified. For example, it has been hypothesiza_d that Alzheimer's disease results from a decrease or loss of nerve growth factor (NGF). It has thus been proposed to treat SDAT patients with exogenous nerve growth factor or other neurotrophic 25 proteins,, such as brain derived growth factcr, glial derived growth factor, ciliary neurotrophic factor and neurotropin-3, to increase the survival of degenerating neuronal populations.
The present invention provides compounds containing small molecule FKBP rotamase inhibitors for 5 enhancing neurite outgrowth, and promoting neuronal growth and regeneration in various neuropathological situations 'where neuronal repair can be facilitated, including: peripheral nerve damage caused by physical injury or disease state such as diabetes; physical 10 damage to the central nervous system (spinal cord and brain); brain damage associated with stroke; and neurologica:L disorders relating to neurodegeneration, such as Parkinson's disease, SDAT (Alzheimer's disease) and amyotrophic lateral sclerosis. The 15 inventive compounds are also useful for treating alopecia, promoting hair growth, treating vision disorder, improving vision, treating memory impairment and enhancing memory performance in an animal.
2 0 SU1~1ARY OF THE INVENTION
The present invention relates to neurotrophic iow molecular weight, small molecule cyclic ester and amide derivatives having an affinity for FKBP-type immunophilins. Once bound to these proteins, the 25 compounds ar-e potent inhibitors of the enzyme activity associated with immunophilin proteins, particularly peptidyl-prolyl isomerase, or rotamase, enzyme -activity. The compounds may or may not exert immunosuppre,ssive activity.
Specifically, the present invention relates to a 5 compound of formula I

I

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B, taken together with the carbon atoms to 15 which they are respectively attached, form a 5-7 membered saturated or unsaturated carbocyclic or heterocyclic ring, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group c:o;nsisting of 0, S, S0, SO2, N, NH, and NR;
20 R, R1, and RZ are independently C1-C9 straight or branched chain alkyl,. Cz-C9 straight or branched chain alkenyl, C-,-C9 cycloalkyl, C3-C9 cycloalkenyl, or Ar, wherein said R, R1, and RZ are independently unsubstitut:ed or substituted with one or 25 substituent(s);
I s Ar is an aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring having an individual ring size of 5-9 members, said heterocyclic ring containing one or more heteroatom(s) independently selected from 5 the group consisting of 0, S, S0, SO2, N, NH and NR;
W and X are independently 0, S, CHZ or H2;
Y is 0 or S; and Z is 0, NH or NR.
A preferred embodiment of this invention is a 10 compound of formula II

R~
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A arad B, taken together with the nitrogen and 20 carbon atoms to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of 0, S, S0, SOz, N, NH and NR;
25 R and R, are independently C1-C9 straight or branched chain alkyl, Cz-C9 straight or branched chain ~B

alkenyl, C3-C9 cycloalkyl, C3-C9 cycloalkenyl, or Ar, wherein said R and R1 are independently unsubstituted.
or substituted with one or more substituent(s);
RZ is C3-C9 cycloalkyl, C3-C9 cycloalkenyl or Ar, 5 wherein said cycloalkyl or cycloalkenyl is unsubstitut:ed or substituted with ()T1P nr ,nn,....
substituent.(s), or said Ar is substituted with one or more substituent(s);
Ar is an aromatic, mono-, bi- or tricyclic, 10 carbo- or heterocyclic ring having an individual ring size of 5-9 members, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of 0, S, S0, SOZ, N, NH and NR;
W and .X are independently 0, S, CHZ or HZ;
15 Y is 0 or S; and Z is 0, NH or NR.
Another preferred embodiment is a compound of formula III

U~~n v ~~~ III
25 or a pharmaceutically acceptable salt, ester, or solvate thereof.

The present invention also relates to a -' pharmaceutic:al composition comprising an effective amount of the compound of formula I, II or ITI, and a pharmaceutically acceptable carrier.
5 The present invention further relates to a method of effecting a neuronal activity in an animal, comprising administering to said animal an effective amount of the compound of formula I, II or III.

Definitions "Alkyl''' means a branched or unbranched saturated hydrocarbon chain containing 1 to 6 carbon atoms, such as methyl, ethyl, propyl, iso-propyl, butyl, iso-15 butyl, tert~-butyl, n-pentyl, n-hexyl, and the like, unless otherwise indicated.
"Alkoxy" means the group -OR wherein R is alkyl as herein defined. Preferably, R is a branched or unbranched saturated hydrocarbon chain containing 1 to 20 3 carbon atoms.
"Alopec:ia" refers to deficient hair growth and partial or complete loss of hair, including without limitation androgenic alopecia (male pattern baldness), toxic alopecia, alopecia senilis, alopecia 25 areata, al.opecia pelada and trichotillomania.
Alopecia reaults when the pilar cycle is disturbed.

The most fz~equent phenomenon is a shortening of the hair growth or anagen phase due to cessation of cell proliferation. This results in an early onset of the catagen phase, and consequently a large number of 5 hairs in the telogen phase during which the follicles are detached from the dermal papillae, and the hairs fall out. Alopecia has a number of etiologies, including genetic factors, aging, local and systemic diseases, febrile conditions, mental stresses, 10 hormonal problems, and secondary effects of drugs.
"Enhancing memory performance" refers to improving or increasing the mental faculty by which to register, retain or recall past experiences, knowledge, ideas, sensations, thoughts or impressions.
15 "Eye" refers to the anatomical structure responsible for vision in humans and other animals, and encompasses the following anatomical structures, without limitation: lens, vitreous body, ciliary body;
posterior chamber, anterior chamber, pupil, cornea, 20 iris, canal. of Schlemm, zonules of Zinn, limbus, conjunctiva,. choroid, retina, central vessels of the retina, optic nerve, fovea centralis, macula lutea, and sclera.
"Halo" means fluoro, chloro, bromo, or iodo, 25 unless otherwise indicated.

"Isomers" refer to different compounds that have the same molecular formula. "Stereoisomers" are isomers than differ only in the way the atoms are arranged is space. "Enantiomers" are a pair of 5 stereoisomers that are non-superimposable mirror images of each other. "Diastereoisomers" are stereoisomers which are not mirror images of each other. "Racemic mixture" means a mixture containing equal parts of individual enantiomers. "Non-racemic 10 mixture" i~; a mixture containing unequal parts of individual enantiomers or stereoisomers.
"Memory impairment" refers to a diminished mental registration, retention or recall of past experiences, knowledge, ideas, sensations, thoughts or impressions.
15 Memory impairment may affect short and long-term information retention, facility with spatial relationships, memory (rehearsal) strategies, and verbal retrieval and production. Common causes of memory impairment are age, severe head trauma, brain 20 anoxia or i.schemia, alcoholic-nutritional diseases, and drug intoxications. Examples of memory impairment include, without limitation, benign forgetfulness, amnesia and any disorder in which memory deficiency is present, such as Korsakoff's amnesic psychosis, 25 dementia and learning disorders.

"Ophthalmological" refers to anything about or concerning the eye, without limitation, and is used interchangeably with "ocular," "ophthalmic,"
"ophthalmologic," and other such terms, without 5 limitation.
"Pharmaceutically acceptable salt, ester, or solvate" refers to a salt, ester, or solvate of a subject compound which possesses the desired pharmacological activity and which is neither 10 biologically nor otherwise undesirable. A salt, ester, or solvate can be formed with inorganic acids such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, 15 cyclopentanc=propionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, gluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, 20 methanesulfonate, naphthylate, 2-naphthalenesulfonate, nicotinate, oxalate, sulfate, thiocyanate, tosylate and undecanoate. Examples of base salts, esters, or solvates include ammonium salts; alkali metal salts, such as sodium and potassium salts; alkaline earth 25 metal salts, such as calcium and magnesium salts;
salts with organic bases, such as dicyclohexylamine i3 salts; N-methyl-D-glucamine; and salts with amino -' acids, such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quarternized with such agents as lower alkyl halides, 5 such as methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl, and diamyl sulfates; long chain halides, such as decyl, lauryl, myristyl, and stearyl chl.arides, bromides, and iodides; aralkyl 10 halides, su~~h as benzyl and phenethyl bromides; and others. Wager or oil-soluble or dispersible products are thereby obtained.
"Pheny:°:" includes all possible isomeric phenyl radicals, optionally monosubstituted or multi-substi 15 tuted with substituents selected from the group consisting of alkyl, alkoxy, hydroxy, halo, and haloalkyl.
"Pilar cycle" refers to the life cycle of hair follicles, and includes three phases:
20 (1) the anagen phase, the period of active hair growth which, insofar as scalp hair is concerned, lasts about three to five years;
(2) the catagen phase, the period when growth stops and the follicle atrophies which, 25 insofar as scalp hair is concerned, lasts w about one to two weeks; and (3) the telogen phase, the rest period when hair progressively separates and finally falls out which, insofar as scalp hair is concerned, lasts about three to four months.
5 Normally 80 to 90 percent of the follicles are in the anagen phase, less than 1 percent being in the catagen phase, and the rest being in the telogen phase. In the telogen phase, hair is uniform in diameter with a slightly bulbous, non-pigmented root. By contrast, in 10 the.anagen phase, hair has a large colored bulb at its root.
"Preventing vision degeneration" as used herein includes the ability to prevent degeneration of vision in patients newly diagnosed as having a degenerative 15 disease affecting vision, or at risk of developing a new degenerative disease affecting vision, and for preventing further degeneration of vision in patients who are already suffering from or have symptoms of a degenerative disease affecting vision.
20 "Promot.ing hair growth" refers to maintaining, inducing, stimulating, accelerating, or revitalizing the germination of hair.
"Promoting vision regeneration" refers to maintaining, improving, stimulating or accelerating 25 recovery of, or revitalizing one or more components of the visual system in a manner which improves or enhances vision, either in the presence or absence of -- any ophthalmologic disorder, disease, or injury.
"Treating" refers to:
(i) preventing a disease and/or condition from 5 occurring in a subject which may be predisposed to the disease and/or condition but has not yet been diag nosed as having it;
(ii) inhibiting the disease and/or condition, i.e., arresting its development; or 10 (iii) relieving the disease and/or condition, i.e., causing regression of the disease and/or condi-tion.
"Treating alopecia" refers to:
(i) preventing alopecia in an animal which may be 15 predisposed to alopecia; and/or (ii) inhibiting, retarding or reducing alopecia;
and/or (iii) promoting hair growth; and/or (iv) prolonging the anagen phase of the hair 20 cycle; and/or (v) converting vellus hair to growth as terminal hair. Terminal hair is coarse, pigmented, long hair in which the: bulb of the hair follicle is seated deep in the dermis. Vellus hair, on the other hand, is 25 fine, thin, non-pigmented short hair in which the hair bulb _.is loc:ated superficially in the dermis. As WO 00/17161 PC'T/US99/21290 alopecia progresses, the hairs change from the terminal to the vellus type.
"Vision", as used herein, refers to the ability of humans and other animals to process images, and is 5 used interchangeably with "sight", "seeing", and other such terms, without limitation.
"Vision disorder" refers to any disorder that affects or involves vision, including without limitation visual impairment, orbital disorders, 10 disorders of the lacrimal apparatus, disorders of the eyelids, disorders of the conjunctiva, disorders of the cornea, cataracts, disorders of the uveal tract, disorders of the retina, disorders of the optic nerve or visual pathways, free radical induced eye disorders 15 and diseases, immunologically-mediated eye disorders and diseases, eye injuries, and symptoms and complications of eye disease, eye disorder, or eye injury.
"Visua:L impairment" refers to any dysfunction in 20 vision including without limitation disturbances or diminution in vision (e. g., binocular, central, peripheral, scotopic), visual acuity for objects near and for, visual field, ocular motility, color perception, adaptation to light and dark, 25 accommodation, refraction, and lacrimation. See Physicians' Desk Reference (PDR) for Ophthalmology, 16th Edition, 6:47 (1988) .
Compounds of the Invention The low molecular weight, small molecule FKBP
inhibitor compounds of this invention have an affinity for FKBP-type immunophilins, such as FKBP12. When the compounds of this invention are bound to an FKBP-type immunophilin, they have been found to inhibit the 10 prolyl-peptidyl cis-trans isomerase activity, or rotamase, activity of the binding protein.
Unexpectedly, the compounds are effective in stimulating neurite growth, as well as treating alopecia, promoting hair growth, treating vision 15 disorders, improving vision, treating memory impairment, and enhancing memory performance in an animal. The compounds may or may not be immunosuppre,ssive.

The cyclic ester or amide derivative may be a compound of :Formula I

I B
I

or a pharmaceutically acceptable salt, ester, or solvate thE~reof, wherein:
A and B, taken together with the carbon atoms to 10 which they are attached, form a 5-7 membered saturated or unsaturated carbocyclic or heterocyclic ring, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of 0, S, S0, SO2, N, NH, and NR:
15 R, R~ and Rz are independently C1-C9 straight or branched chain alkyl, CZ-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, Cj-C9 cycloalkeny:L, or Ar, wherein said R, R1 and R2 are independently unsubstituted or substituted with one or more 20 substituent(s) and the carbon atoms of said alkyl, alkenyl, cycloaikyl, and cycloalkenyl are independently unsubstituted or substituted with one or more heteroatom(s);
Ar is an aromatic, mono-, bi- or tricyclic, 25 carba- or h~~terocyclic ring having an individual ring size of 5-9 members, said heterocyclic ring containing '9 one or more heteroatom(s) independently selected from the-group consisting of 0, S, S0, SO2, N, NH and NR;
W and X area independently 0, S, CHZ or Hz;
Y is 0 or ~'>~ and Z is 0, NH, or NR.
FORMULA II
In a preferred embodiment, the cyclic ester or amide derivative is a compound of formula II
B
A
N Z'RZ
i ~X Y
ii is R1 or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B, taken together with the nitrogen and carbon atoms to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of 0, S, S0, SOZ, N, NH and NR;
R and R.1 are independently C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C.~ cycloalkyl, C3-C9 cycloalkenyl, ar Ar, wherein said R and R1 are independently unsubstituted or substituted with one or more substituent(s), and the carbon atoms of said alkyl, alkenyl, cycloalkyl, and cycloalkenyl are independently unsubstituted or 5 substituted with one or more heteroatom(s);
RZ is C3-C9 cycloalkyl, C3-C9 cycloalkenyl or Ar, wherein said RZ is unsubstituted or substituted with one or more substituent(s), and the carbon atoms of said cycloalkyl and cycloalkenyl are independently 10 substituted with one or more heteroatom(s);
Ar is an aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring having an individual ring size of 5-9 members, said heterocyclic ring containing one or more heteroatom(s) independently selected from 15 the group consisting of 0, S, S0, SO2, N, NH and NR~
W and X are independently 0, S, CHz or H2;
Y is 0 or S; and Z is 0, NH or NR.
In another preferred embodiment, RZ is substituted 20 with (Ar)~, and n is 1-2.
FORMULA III
In the' most preferred embodiment, the cyclic ester or amide derivative is 4,9-diphenylcyclohexl 25 (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-pyrrolidine-2-carbaxylate, a compound of formula III

or a pharTnaceutically acceptable salt, ester, or solvate thereof.
In the compounds cf formulas T-I~1, possible 10 substituents of R, R, and R~ are C:-C9 straight or branched chain alkyl, CZ-C9 straight or branched chain alkenyl, C1-C9 alkoxy, C~-C9 alkenyloxy, phenoxy, benzyloxy, C3-Ce cycloalkyl, CS-C, cycloalkenyl, hydroxy, carboxy, carbonyl, amino, amido, cvano.
15 isocyano, vitro, nitroso, nitrilo, isonitrilo, imino, azo, diazc, sulfonyl, sulfoxy, thio, thiocarbonyl, thiocyano, formanilido, thioformamido, sulfhydryl, halo, haloa:lkyl, trifluoromethyl, and carbocyclic and heterocyclic moieties. Carbocyclic moieties include 20 alicyclic and aromatic structures.
ExamplE=_s of useful carbocyclic and heterocyclic moieties include, without limitation, phenyl, benzyl, naphthyl, in denyl, azulenyl, fluorenyl, anthracenyl, indolyl, i.soindolyl, indolinyl, benzofuranyl, 25 benzothiophenyl, indazolyl, benzimidazolyl, benzthiazcl~rl, tetrahydrofuranyl, tetrahydropyranyl, pyridyl, pyrrolyl, pyrroiidinyl, pyridinyl, pyrimidinyl., purinyl, a_uinolinyl, isoquinolinyl, tetrahydrocruinolinyl, quinolizinyl, furyl, thiophenyl, imidazolyl, oxazolyl, benzoxazolyl, thiazolyl, 5 isoxazolyl, isotriazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, trithianyl, indolizinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, thienyl, tetrahydroisoquinolinyl, cinnolinyl, phthalazinyl, 10 quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and phenoxazinyl.
All t:he compounds of formulas I-III possess asymmetric centers and thus can be produced as 15 mixtures of stereoisomers or as individual R- and S
stereoisomers. The individual stereoisomers may be obtained by using an optically active starting material, by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage 20 of the synthesis, or by resolving the compounds of formulas T-III. It is understood that the compounds of formulas i-III encompass individual stereoisomers as well as mixtures (racemic and non-racemic) of stereoisomers. S-stereoisomers are most preferred.

WO 00/17161 PC'f/US99/21290 Pharmaceutical Compositions of the Invention The present invention also relates to a pharma-ceutical composition comprising:
(i) a:n effective amount of a compound of formula 5 I, II or III; and (ii) a pharmaceutically acceptable carrier.
Preferred compounds of formula I and II are set forth above.
In a preferred embodiment of the inventive 10 pharmaceuti~~al composition, the amount of the compound of formula .C, II or III is effective for binding to an FKBP-type immunophilin.
In another preferred embodiment, the amount of the compound of formula I, II or III is effective for 15 effecting a neuronal activity in an animal.
Methods of the Invention The compounds of the present invention have an affinity for the FK506 binding protein, particularly FKBP12, which is present in the brain. When the 20 inventive compounds bind to FKBP in the brain, they exhibit Pxcellent neurotrophic activity. This activity is useful in the stimulation of damaged neurons, the promotion of neuronal regeneration, the prevention of neurodegeneration, and the treatment of 25 several neurological disorders known to be associated with neuronal degeneration and peripheral neuropathies .
For tine foregoing reasons, the present invention further relates to a method of effecting a neuronal 5 activity in an animal, comprising administering to said animal an effective amount of a compound of formula I, II or III.
Prefe::red compounds of formula I and II are set forth above.
10 In a ~>referred embodiment, the neuronal activity is selected from the group consisting of stimulation of damagE~d neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.
15 The neurological disorders that may be treated include but are not limited to: trigeminal neuralgia;
glossopharyngeal neuralgia; Bell's Palsy; myasthenia gravis; muscular dystrophy; amyotrophic lateral sclerosis; progressive muscular atrophy; progressive 20 bulbar inherited muscular atrophy; herniated, ruptured or prolapsed invertebrate disk syndromes; cervical spondylosis; plexus disorders; thoracic outlet destruction syndromes; peripheral neuropathies such as those caused by lead, dapsone, ticks, porphyria or 25 Guillain-Barre syndrome; Alzheimer's disease; and aark-inson's disease.

WO 00/17161 PCTlUS99/21290 The ;~cmaounds of the present invention are particular:Ly useful for treating a neurological disorder :>elected from the group consisting of:
peripheral neuropathy caused by physical injury or 5 disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegene~ration. Examples of neurological disorders relating to neurodegeneration are ?.lzheimer' s Disease, 10 Parkinson's Disease and amyotrophic lateral sclerosis.
For these purposes, the compounds of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir in 15 dosage formulations containing conventional non-toxic pharmaceutically-acceptable carriers, adjuvants and vehicles. 'rhe term parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraperitoneally, intrathecally, intraventricularly, 20 intrasternal and intracranial injection or infusion techniques.
To be effective therapeutically as central nervous system targets the immunophilin-drug complex should readily penetrate the blood-brain barrier when 25 peripherally administered. Compounds of this inve~tien which cannot penetrate the blood-brain barrier can be effectively administered by an w intraventr_cular route.
The compounds may be in the form of a sterile injectable preparation, for example as a sterile 5 injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques know in thE~ art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution 10 or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In 15 addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids such as oleic acid and its glyceride derivatives find use in 20 the preparation of injectables, olive oil or castor oil, espec=:ally in their polyoxyethylated versions.
These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant.
Additionally, the compounds may be administered 25 orally iri the form of capsules or tablets, for example, car as an aqueous suspension or solution. In the case oi= tablets for oral use, carriers which are commonly used include lactose and corn starch.
Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a 5 capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and/or flavoring and/or 10 coloring agents may be added.
The compounds of this invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-15 irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
Such materials include cocoa butter, beeswax and polyethylene glycols.
20 The compounds of this invention may also be administered optically, especially when the conditions addressed for treatment involve areas or organs readily accessible by topical application, including neurologica:L disorders of the eye, the skin, or the 25 lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas.

For ophthalmic use, the compounds can be -~ formulated as micronized suspensions in isotonic, pH
adjusted sterile saline, or, preferably, as solutions is isotonic,. pH adjusted sterile saline, either with 5 or without a preservative such as benzylalkonium chloride. Alternatively for the ophthalmic uses the compounds m,ay be formulated in an ointment such as petrolatum.
For application topically to the skin, the 10 compounds can be formulated in a suitable ointment containing the compound suspended or dissolved in, for example, a mixture with one or more of the following:
mineral oil, liquid petrolatum, white petrolatum, propylene c~iycol, polyoxyethy~ene polyoxypropylene 15 compound, emulsifying wax and water. Alternatively, the compounds can be formulated in a suitable lotion or cream containing the active compound suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, 20 polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
Topica:L application for the lower intestinal tract an be effected in a rectal suppository formulation (see above) or in a suitable enema 25 formulation.

Dosage' levels on the order of about .Img to about 10,000 mg. of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels of about O.img to about 1,000 mg.
5 The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
T_t is understood, however, that a specific dose 10 level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the severity 15 of the particular disease being treated and form of administration.
The compounds can be administered with other neurotrophic agents such as neurotrophic growth factor (NGF), glia.i. derived growth factor, brain derived 20 growth factor, ciliary neurotrophic factor, and neurotropin--:3. The dosage level of other neurotrophic drugs will depend upon the factors previously stated and the ns~urotrophic effectiveness of the drug combination.

K Test Procedure Inhibition of the peptidyl-prolyl isomerase (rotamase) activity of the inventive compounds can be evaluated by known methods described in the literature 5 (Harding, M.W. et al. Nature 341: 758-760 (1989); Holt et al. J. A,m. Chem. Soc. 115: 9923 -9938). These values are obtained as apparent K,'s and are presented in Table I. The cis-traps isomerization of an alanine-proline bond in a model substrate, N-succinyl-Ala-Ala-10 Pro-Phe-p-n.itroanilide, is monitored spectro-photometrically in a chymotrypsin-coupled assay, which releases para-nitroanilide from the traps form of the substrate. The inhibition of this reaction caused by the addition of different concentrations of inhibitor 15 is determined, and the data is analyzed as a change in first-order rate constant as a function of inhibitor concentraticn to yield the apparent K; values.
In a p~_astic cuvette are added 950 mL of ice cold assay buffer (25 mM HEPES, pH 7.8, 100 mM NaCl), 10 mL
20 of FKBP (2.5 mM in 10 mM Tris-C1 pH 7.5, 100 mM NaCl, 1 mM dithiothreitol), 25 mL of chymotrypsin (50 mg/mL
in 1 mM HC1', and 10 mL of test compound at various concentrations in dimethyl sulfoxide. The reaction is initiated oy the addition of 5 mL of substrate 25 (succinyl-Ala-Phe-Pro-Phe-para-nitroanilide, 5 mg/mL
in 2.35 mM LiCl in trifluoroethanol).

The absorbance at 390 nM versus time is monitored for 90 sec using a spectrophotometer and the rate constants are determined from the absorbance versus time data files .
5 Data fo r these experiments is presented in Table I.
Table z Compound Ki n 10 ~ o \ /

In mamrnalian cells, FKBP-12 complexes with the inositol triphosphate receptor (IP3R) and the ryanodine 15 receptor (RyR). It is believed that the neurotrophic compounds of this invention disassociates FKBP-l2 from these complexes causing the calcium channel to become "leaky" (Cameron et al., 1995). Calcium fluxes are involved in neurite extensions so that the IP3R
20 receptor and the ryanodine receptor might be involved in the neurotrophic effects of drugs. Since the drugs bind to the .same site as FKBP-12 as the IP3R receptor, one could assume that the drugs displace the channels from FKBP-12.

Chick Dorsal Root Gan lion Cultures and Neurite Outaro~th Dorsal root ganglia are dissected from chick embryos of ten day gestation. Whole ganglion explants 5 are cultured on thin layer Matrigel-coated 12 well plates with Liebovitz L15 plus high glucose media supplemented with 2 mM glutamine and 10$ fetal calf serum, and also containing IO ~M cytosine ~i-D
arabinofuranoside (Ara C) at 37°C in an environment IO containing _'i~ CO2. Twenty-four hours later, the DRGs are treated with various concentrations of nerve growth factor (NGF), immunophilin ligands, or combination~~ of NFG plus drugs. Forty-eight hours after drug treatment, the ganglia are visualized under 15 phase contrast or Hoffman Modulation contrast with a Zeiss Axiove:rt inverted microscope. Photomicrographs of the explants are made, and neurite outgrowth is quantitated. Neurites longer than the DRG diameter are counted as positive, with total number of neurites 20 quantitated per each experimental condition. Three to four DRGs are cultured per well, and each treatment is performed in duplicate. The compounds of the present invention n~romote neurite outgrowth in sensory neurons.

Sciatic Nerve Axotomy Six-week old male Sprague-Dawley rats are anesthetized, and the sciatic nerve exposed and crushed, at: the level of the hip, by forceps. Test 5 compounds or vehicle are administered subcutaneously just prior to the lesion and daily for the following 18 days.. Sections of the sciatic nerve are stained with Holme:> silver stain to quantify the number of axons, and Luxol fast blue to quantify the level of 10 myelination. Eighteen days after lesion, there is a significant decrease in the number of axons (50~
decrease as compared to non-lesioned control) and degree of myelination (90$ decrease as compared to non-lesioned control) in animals treated with vehicle.
15 Administration of neuroimmunophilin FKBP ligands, which are compounds related to those of the present invention, just prior to the lesion and daily for 18 days following the lesion, results in significant regeneration of both axon number and the degree of 20 myelination as compared to vehicle treated animals.
The signif=scant efficacy of neuroimmunophilin FKBP
ligands is r_onsistent with their potent activity in inhibiting rotamase activity and stimulating neurite outgrowth in chick DRGs.

MPTP Model of Parkinson's Disease in Mice The neurotrophic effects of the compounds of the present invention are further demonstrated in an animal model of neurodegenerative disease: MPTP
5 lesioning of: dopaminergic neurons in mice is used as an animal model of Parkinson's Disease. Four week old male CD1 white mice are dosed i . p . with 30 mg/kg of MPTP for 5 days. A cyclic ester or amide derivative (10-40 mg/kg), or vehicle, is administered s.c. along 10 with the MPf P far 5 days, as well as for an additional 5 days following cessation of MPTP treatment. At 18 days following MPTP treatment, the animals are sacrificed and the striata are dissected and homogenized.. Binding of [3H]CFT, a radioligand for the 15 dopamine transporter, to the stiatal membranes is done to quantitate the level of the dopamine transporter (DAT) fol:Lowing lesion and drug treatment.
Immunostaining is performed on saggital and coronal brain sections using anti-tyrosine hydoxylase Ig to 20 quantitate survival and recovery of dopaminergic neurons. In animals treated with MPTP and vehicle, a substantial loss of functional dopaminergic terminals is observed as compared to non-lesioned animals.
Lesioned animals receiving cyclic ester or amide 25 derivatives show a nearly quantitative recovery of TH-stained dopaminergic neurons.

These experiments demonstrate the significant recovery W functional dopaminergic terminals, as assayed by [3H]-CFT binding, relative to animals receiving MPTP but not a cyclic ester ar amide 5 derivative. Animals receiving 40 mg/kg of cyclic ester or amide derivative in addition to MPTP manifest greater recovery of [3H]-CFT binding. Immunostaining for tyrosine hydroxylase (a marker of viable dopaminergic: neurons) in the striatum, the nigra, and 10 the medial forebrain bundle, shows a clear and marked recovery of functional neurons in animals that receive a cyclic ester or amide derivative, as compared to animals that received lesioning agent but no drug (MPTP/Vehicl_e) .

Data on Related Compounds U.S. Patent Application No. 09/089,416, filed June 3, 1998 is incorporated herein by reference.
Said application includes K: data for various 20 neuroimmunophilin FKBP ligands, which are related to the compounds of the present invention (see Tables IX-XVI).
U.S. Patent Application No. 08/479,436, filed June 7, 1995, is also incorporated herein by 25 reference. Said application includes neurite outgrowth and MPTP recovery data for various neuroimmunophilin FKBP ligands, which are related to -- the compounca of the present invention (see Table II
and Figures ~~-8, respectively).
U.S. Patent Application No. 08/719,947, filed 5 September 2.';, 1996, is further incorporated herein by reference. Said application includes neurite outgrowth data for various neuroimmunophilin FKBP
ligands, which are related to the compounds of the present invention (see Table III, Figures 1(A-C), and 10 F figures 2 ( A--C ) ) .
EXA~MPI~E S
The following examples are illustrative of the present invention and are not intended to be 15 limitations thereon. Unless otherwise indicated, all percentages are based on 100 by weight of the final compound or ;composition.
The compounds of the present invention can be readily prepared by standard techniques of organic 20 chemistry, utilizing the general synthetic pathway depicted below in Scheme I. Precursor compounds can be prepared by methods known to those skilled in the art.

Scheme I

a o RLi or RMgX
~~is N -i 5 0~0 0 aai, u~ Yz N off' MeCfU H20 N a Coupling method _ ~ C) 'R R
C;~Y-Z
N
10 0~0 0 ~' ~R

Synthesis of 4,4-Diphenylcyclohexl (2S)-1-(3,3-15 dimethyl-2-oxopentanoyl)-pyrrolidine-2-carboxylate (Formula III) 1. Synthesis of methyl (2S)-1-(1,2-dioxo-2-methox~r ethyl)-2-py:rrolidinecarboxylate.
A solution of L-proline methyl ester 20 hydrochloride (3.08 g; 18.60 mmol) in dry methylene chloride was cooled to 0°C and treated with triethylamine (3.92 g; 38.74 mmol; 2.1 eq). After stirring ths~ formed slurry under a nitrogen atmosphere for 15 min, a solution of methyl oxalyl chloride (3.20 25 g; 26.12 mmol) in methylene chloride (45 mL) was added dropwise. T he resulting mixture was stirred at 0°C.for 1.5 hr. After filtering to remove solids, the organic phase was washed with water, dried over MgSOa and concentrated. The crude residue was purified on a silica gel c:alumn, eluting with 50~ ethyl acetate in 5 hexane, to obtain 3.52 g (88~) of the product as a reddish oil. Mixture of cis-traps amide rotamers; data for traps rotamer given. 1H NMR (CDC13): d 1.93 (dm, 2H) ; 2.17 (m, 2H) ; 3. 62 (m, 2H) ; 3.71 (s, 3H) ; 3.79, 3.84 ( s, 3H total); 4.86 (dd, 1H, J = 8.4, 3.3).
10 2. Synthesis of methyl (2S)-1-(1,2-dioxo-3,3-dimethyloentvl)-2-pyrrolidinecarboxylate.
A so:Lution of methyl (2S)-1-(1,2-dioxo-2-methoxyethyl)-2-pyrrolidinecarboxylate (2.35 g; 10.90 mmol) in 30 mL of tetrahydrofuran (THF) was cooled to 15 -78°C and treated with 14.2 mL of a 1.0 M solution of 1,1-dimethylpropylmagnesium chloride in THF. After stirring the resulting homogeneous mixture at -78°C for three hours,, the mixture was poured into saturated ammonium ch:~Laride (100 mL) and extracted into ethyl 20 acetate. The organic phase was washed with water, dried, and concentrated, and the crude material obtained upon removal of the solvent was purified on a silica gel column, eluting with 25% ethyl acetate in hexane, to obtain 2.10 g (75~) of the oxamate as a 25 colorless oi-.~. 'H NMR (CDC13) : d 0. 88 (t, 3H) ; 1.22, 1 .26 w(s, 3H each) ; 1.7:~ (dm, 2H) ; 1.87-2.10 (m, 3H) ;

2.23 (m, 1H); 3.54 (m, 2H); 3.76 (s, 3H); 9.52 (dm, ~1H, J = 8 . 4 , 3 . 4 ) .
3. Synthesis of (2S)-1-(1.2-dioxo-3.3-dimethylnentvl)-2-pvrrolidinecarboxylic acid.
5 A mi:~tture of methyl (2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylate (2.10 g; 8.23 mmol), 1 N LiOH (15 mL), and methanol (50 mL) was stirred at 0"C for 30 min and at room temperature overnight. T:he mixture was acidified to pH 1 with 1 N
10 HC1, diluted with water, and extracted into 100 mL of methylene chloride. The organic extract was washed with brine and concentrated to deliver 1.73 g (87~) of snow-white solid which did not reauire further purification. 1H NMR (CDC13) : d 0. 87 (t, 3H) ; 1.22, 15 1.25 (s, 3H each) ; 1.77 (dm, 2H) ; 2. 02 (m, 2H) ; 2.17 (m, iH) ; 2.25 (m, iH) ; 3. 53 (dd, 2H, J - 10.4, 7. 3) ;
4.55 (dd, 1H, J = 8.6, 4.1) .
9. Synthesis of 4,4-Diphenylc~clohexl (2S~-?-(3,3 dimethyl-2 -oxonentano~l ) -pyrrol idine-2-carbox~rlate 20 (Formula IIIL
A mixture of (2S)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidine-carboxylic acid (600 mg;
2.49 mmol), 4,4-diphenylcyclohexanol (942 mg; 3.73 mmol), dicyclohexylcarbodiimide (822 mg; 3.98 mmol), 25 camphorsulphonic acid (190 mg; 0.8 mmol) and 4-dimetl~ylaminopyridine (100 mg; 0.8 mmoi) in methylene chloride (:?0 mL) was stirred overnight under a nitrogen atmosphere. The reaction mixture was filtered through Celite to remove solids and concentrated in vacuo, and t:he crude material was purified on a flash 5 column (25o ethyl acetate in hexane) to obtain the compound of Formula III as a white solid, m.p. 127.5-128 . 8 °C . '-H NMR (CDC13, 400MHz ) : s 0 . 84 ( t, 3H, J =
7.5); 1.26, 1.28 (s, 3H each); 2.01-2.56 (m, lOH);
2.15-2.28 (m, 2H); 2.98-2.6i (m, 2H); 3.42-3.68 (m, 10 2H); 9.48 (7_H, dd, J = 3.6, 8.5); 4.96 (m, 1H); 7.25-x . 34 (m, lOH ) .
Exaaiiple 2 A patient is suffering from peripheral nerve damage caused by physical injury or disease state such 15 as diabetes. A cyclic ester or amide derivative as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Enhanced neurite outgrowth, and neuronal growth and regeneration are expected to occur 20 following treatment.
Exaa~le 3 A patient is suffering from physical damage to the central nervous system (spinal cord and brain).
A cyclic ester or amide derivative as identified 25 above, or a pharmaceutical composition comprising the same, may be administered to the patient. Enhanced neurite outgrowth, and neuronal growth and -- regeneration are expected to occur following treatment.
Example 4 5 A patient is suffering from brain damage associated with stroke. A cyclic ester or amide derivative as identified above, or a pharmaceutical composition ~~omprising the same, may be administered to the patient. Enhanced neurite outgrowth, and 10 neuronal growth and regeneration are expected to occur following treatment.
Example 5 A patient is suffering from neurodegeneration resulting from Parkinson's disease. A cyclic ester or 15 amide derivative as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Enhanced neurite outgrowth, and neuronal growth and regeneration are expected to occur following treatment.
20 Example 6 A patient is suffering from neurodegeneration resulting from amyotrophic lateral sclerosis. A
cyclic ester or amide derivative as identified above, or a pharmaceutical composition comprising the same, 25 may be aami!zistered to the patient. Enhanced neurite a2 outgrowth, and neuronal growth and regeneration are expected to occur following treatment.
Example 7 A patient is suffering from neurodegeneration 5 resulting from SDAT (Alzheimer's disease). A cyclic ester or amide derivative as identified above, or a pharmaceutical composition comprising the same, may be administered to the patient. Enhanced neurite outgrowth, and neuronal growth and regeneration are 10 expected to occur following treatment.
The invention being thus described, it will be obvious that the same may be varied in many ways.
Such variations are not to be regarded as a departure 15 from the spirit and scope of the invention and all such modifi~~ations are intended to be included within the scope of the following claims.

Claims (44)

WE CLAIM:
1. A. compound of formula I

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B, taken together with the carbon atoms to which they are attached, form a 5-7 membered saturated or unsaturated carbocyclic or heterocyclic ring, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH, and NR;
R, R1, and R2 are independently C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, C3-C9 cycloalkenyl , or Ar, wherein said R, R1, and R2 are independently unsubstituted or substituted with one or substituent(s) and the carbon atoms of said alkyl, alkenyl, cycloalkyl, and cycloalkenyl are independently unsubstituted or substituted with one or more heteroatom(s);

Ar is an aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring having an individual ring size of 5-9 members, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH and NR;
W and X are independently O, S, CH2 or H2;
Y is O or S; and Z is O, NH or NR.
2. The compound of claim 1, wherein said compound is immunosuppressive.
3. The compound of claim 1, wherein said compound is non-immunosuppressive.
4. The compound of claim 1, wherein said compound has an affinity for an FKBP-type immunophilin.
5. The compound of claim 4, wherein the FKBP-type immunophilin is FKBP-12.
6. A compound of formula II

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B, taken together with the nitrogen and carbon atoms to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH and NR;
R and R1 are independently C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, C3-C9 cycloalkenyl, or Ar, wherein said R and R1 are independently unsubstituted or substituted with one or more substituent(s) and the carbon atoms of said alkyl, alkenyl, cycloalkyl, and cycloalkenyl are independently unsubstituted or substituted with one or more heteroatom(s);
R2 is C3-C9 cycloalkyl, C3-C9 cycloalkenyl or Ar, wherein said cycloalkyl or cycloalkenyl is unsubstituted or substituted with one or more substituent(s) and the carbon atoms of said cycloalkyl and cycloalkenyl are independently unsubstituted or substituted with one or more heteroatom(s), or said Ar is substituted with one or more substituent(s);
Ar is an aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring having an individual ring size of 5-9 members, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH and NR;
W and X are independently O, S, CH2 or H2;
Y is O or S; and Z is O, NH or NR.
7. The compound of claim 6, wherein said compound is immunosuppressive.
8. The compound of claim 6, wherein said compound is non-immunosuppressive.
9. The compound of claim 6, wherein said compound has an affinity for an FKBP-type immunophilin.
10. The compound of claim 9, wherein the FKBP-type immunophilin is FKBP-12.
11. The compound of claim 6, wherein:
R2 is substituted with (Ar)n; and n is 1-2.
12. The compound of claim 11, wherein said compound is 4,4-diphenylcyclohexl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-pyrrolidine-2-carboxylate of formula III

or a pharmaceutically acceptable salt, ester, or solvate thereof.
13. A pharmaceutical composition comprising:
(i) an effective amount of a compound of formula I

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B, taken together with the carbon atoms to which they are attached, form a 5-7 membered saturated or unsaturated carbocyclic or heterocyclic ring, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH, and NR;
R, R1, and R2 are independently C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, C3-C9 cycloalkenyl, or Ar, wherein said R, R1, and R2 are independently unsubstituted or substituted with one or substituent(s) and the carbon atoms of said alkyl, alkenyl, cycloalkyl, and cycloalkenyl are independently unsubstituted or substituted with one or more heteroatom(s);
Ar is an aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring having an individual ring size of 5-9 members, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH and NR;
W and X are independently O, S, CH2 or H2:
Y is O or S;
Z is O, NH or NR; and (ii) a pharmaceutically acceptable carrier.
14. The pharmaceutical composition of claim 13, wherein said compound is immunosuppressive.
15. The pharmaceutical composition of claim 13, wherein said compound is non-immunosuppressive.
16. The pharmaceutical composition of claim 13, wherein said compound has an affinity for an FKBP-type immunophilin.
17. The pharmaceutical composition of claim 16, wherein the FKBP-type immunophilin is FKBP-12.
18. The pharmaceutical composition of claim 13, further comprising one or more neurotrophic agent(s).
19. The pharmaceutical composition of claim 18, wherein said one or more neurotrophic agent(s) is/are selected from the group consisting of neurotrophic growth factor (NGF), glial derived growth factor, brain derived growth factor, ciliary neurotrophic factor, and neurotropin-3.
20. A pharmaceutical composition comprising:
(i) an effective amount of a compound of formula II

pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B, taken together with the nitrogen and carbon atoms to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH and NR;
R and R1 are independently C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, C3-C9 cycloalkenyl, or Ar, wherein said. R and R1 are independently unsubstituted or substituted with one or more substituent(s) and the carbon atoms of said alkyl, alkenyl, cycloalkyl, and cycloalkenyl are independently unsubstituted or substituted with one or more heteroatom(s);
R, is C3-C9 cycloalkyl, C3-C9 cycloalkenyl or Ar, wherein said cycloalkyl or cycloalkenyl is unsubstituted or substituted with one or more substituent(s) and the carbon atoms of said cycloalkyl and cycloalkenyl are independently unsubstituted or substituted with one or more heteroatom(s), or said Ar is substituted with one or more substituent(s);
Ar is an aromatic, mono-, bi- or tricyclic, carbo-or heterocyclic ring having an individual ring size of 5-9 members, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH and NR;
W and X are independently O, S, CH2 or H2;
Y is O or S;
Z is O. NH or NR; and (ii) a pharmaceutically acceptable carrier.
21. The pharmaceutical composition of claim 20, wherein said compound is immunosuppressive.
22. The pharmaceutical composition of claim 20, wherein said compound is non-immunosuppressive.
23. The pharmaceutical composition of claim 20, wherein said compound has an affinity for an FKBP-type immunophilin.
24. The pharmaceutical composition of claim 23, wherein the FKBP-type immunophilin is FKBP-12.
25. The pharmaceutical composition of claim 20, wherein:
R2 is substituted with (Ar)n; and n is 1-2.
26. The pharmaceutical composition of claim 25, wherein said compound is 4,4-diphenylcyclohexl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-pyrrolidine-2-carboxylate of formula III

or a pharmaceutically acceptable salt, ester or solvate thereof.
27. A method of effecting a neuronal activity in an animal, comprising administering to said animal an effective amount of a compound of formula I

or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B, taken together with the carbon atoms to which they are attached, form a 5-7 membered saturated or unsaturated carbocyclic or heterocyclic ring, said heterocyclic: ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH and NR;
R, R1 and R2 are independently C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, C3-C9 cycloalkenyl, or Ar, wherein said R, R1 and R2 are independently unsubstituted or substituted with one or substituent(s) and the carbon atoms of said alkyl, alkenyl, cycloalkyl, and cycloalkenyl are independently unsubstituted or substituted with one or more heteroatom(s);
Ar is an aromatic, mono-, bi- or tricyclic, carbo-or heterocyclic ring having an individual ring size of 5-9 members, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH and NR;
W and X are independently O, S, CH2 or H2;
Y is O or S; and Z is O, NH or NR.
28. The method of claim 27, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, and treatment of neurological disorder.
29. The method of claim 28, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration.
30. The method of claim 29, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.
31. The method of claim 27, wherein said compound is immunosuppressive.
32. The method of claim 27, wherein said compound is non-immunosuppressive.
33. The method of claim 27, wherein said compound has an affinity for an FKBP-type immunophilin.
34. The method of claim 33, wherein the FKBP-type immunophilin is FKBP-12.
35. A method of effecting a neuronal activity in an animal, comprising administering to said animal an effective amount of a compound of formula II
or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein:
A and B, taken together with the nitrogen and carbon atoms to which they are respectively attached, form a 5-7 membered saturated or unsaturated heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH and NR;
R and R1 are independently C1-C9 straight or branched chain alkyl, C2-C9 straight or branched chain alkenyl, C3-C9 cycloalkyl, C3-C9 cycloalkenyl, or Ar, wherein said R and R1 are independently unsubstituted or substituted with one or more substituent(s) and the carbon atoms of said alkyl, alkenyl, cycloalkyl, and cycloalkenyl are independently unsubstituted or substituted with one or more heteroatom(s);
R2 is C3-C9 cycloalkyl, C3-C9 cycloalkenyl or Ar, wherein said cycloalkyl or cycloalkenyl is unsubstituted or substituted with one or more substituent(s) and the carbon atoms of said cycloalkyl and cycloalkenyl are independently unsubstituted or substituted with one or more heteroatom(s), or said Ar is substituted with one or more substituent(s);
Ar is an aromatic, mono-, bi- or tricyclic, carbo-or heterocyclic ring having an individual ring size of 5-9 members, said heterocyclic ring containing one or more heteroatom(s) independently selected from the group consisting of O, S, SO, SO2, N, NH and NR;
W and X are independently O, S, CH2 or H2;

Y is O or S; and Z is O, NH or NR.
36. The method of claim 35, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of neurological disorder.
37. The method of claim 36, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorder relating to neurodegeneration.
38. The method of claim 37, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's Disease, Parkihson's Disease, and amyotrophic lateral sclerosis.
39. The method of claim 35, wherein said compound is immunosuppressive.
40. The method of claim 35, wherein said compound is non-immunosuppressive.
41. The method of claim 35, wherein said compound has an affinity for an FKBP-type immunophilin.
42. The method of claim 41, wherein the FKBP-type immunophilin is FKBP-12.
43. The method of claim 35, wherein:
R2 is substituted with (Ar)n; and n is 1-2.
44. The method of claim 43, wherein said compound is 4,4-diphenylcyclohexl (2S)-1-(3,3-dimethyl-2-oxopentanoyl)-pyrrolidine-2-carboxylate of formula III
or a pharmaceutically acceptable salt, ester, or solvate thereof.
CA002341036A 1998-09-21 1999-09-17 Cyclic ester or amide derivatives Abandoned CA2341036A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/157,566 US6462072B1 (en) 1998-09-21 1998-09-21 Cyclic ester or amide derivatives
US09/157,566 1998-09-21
PCT/US1999/021290 WO2000017161A1 (en) 1998-09-21 1999-09-17 Cyclic ester or amide derivatives

Publications (1)

Publication Number Publication Date
CA2341036A1 true CA2341036A1 (en) 2000-03-30

Family

ID=22564303

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002341036A Abandoned CA2341036A1 (en) 1998-09-21 1999-09-17 Cyclic ester or amide derivatives

Country Status (11)

Country Link
US (1) US6462072B1 (en)
EP (1) EP1115703A1 (en)
JP (1) JP2002526474A (en)
KR (1) KR20010089253A (en)
CN (1) CN1323294A (en)
AU (1) AU6390599A (en)
CA (1) CA2341036A1 (en)
HU (1) HUP0103565A3 (en)
IL (1) IL141552A0 (en)
WO (1) WO2000017161A1 (en)
ZA (1) ZA200101934B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60129794T2 (en) * 2000-02-15 2007-12-06 Sugen, Inc., South San Francisco PYRROL SUBSTITUTED INDOLIN-2-ON PROTEIN KINASE INHIBITORS
AR042586A1 (en) * 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
CA2462950A1 (en) 2001-10-10 2003-04-17 Sugen, Inc. 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070361A (en) 1977-04-21 1978-01-24 E. R. Squibb & Sons, Inc. Mercaptoalkylsulfonyl proline and pipecolic acid and esters thereof
US4206137A (en) 1978-03-27 1980-06-03 E. R. Squibb & Sons, Inc. Thioalkanoylalkanoic acid compounds
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
JPS55160757A (en) 1979-05-31 1980-12-13 Sumitomo Chem Co Ltd Novel cyclopentanecarboxylic acid derivative and its preparation
US4578474A (en) 1980-06-23 1986-03-25 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4310461A (en) 1980-06-23 1982-01-12 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4390695A (en) 1980-06-23 1983-06-28 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
GR75019B (en) 1980-09-17 1984-07-12 Univ Miami
LU88621I2 (en) 1980-10-23 1995-09-01 Schering Corp Sandopril
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
ZA826022B (en) 1981-08-21 1983-08-31 Univ Miami Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides
EP0088350B1 (en) 1982-03-08 1985-02-20 Schering Corporation Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them
US4531964A (en) 1982-09-13 1985-07-30 Nippon Kayaku Kabushiki Kaisha Heterocyclic compound and a herbicidal composition containing said compound
US4574079A (en) 1983-05-27 1986-03-04 Gavras Haralambos P Radiolabeled angiotensin converting enzyme inhibitors for radiolabeling mammalian organ sites
US4593102A (en) 1984-04-10 1986-06-03 A. H. Robins Company, Inc. N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position
DE3508251A1 (en) 1985-03-08 1986-09-11 Merck Patent Gmbh, 6100 Darmstadt Dipeptides
CN86101850A (en) 1985-03-22 1987-02-04 森得克斯(美国)有限公司 N, the manufacture method and the purposes of N '-dialkyl group guanidine radicals dipeptides
EP0260118B1 (en) 1986-09-10 1991-12-04 Syntex (U.S.A.) Inc. Selective amidination of diamines
IT1206078B (en) 1987-06-03 1989-04-14 Polifarma Spa PROCEDURE FOR THE PRODUCTION OF 3-INDOLPIRUVIC ACID AND ITS DERIVATIVES THEIR PHARMACEUTICAL USE
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
IL90872A0 (en) 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
DE3931051A1 (en) 1988-09-22 1990-03-29 Hoechst Ag New herbicidal amine salts of herbicidal acids
EP0378318A1 (en) 1989-01-11 1990-07-18 Merck & Co. Inc. Process for synthesis of FK-506 and tricarbonyl intermediates
WO1990012805A1 (en) 1989-04-15 1990-11-01 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Postostatin and related compound thereof, or their salts
US5164525A (en) 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
NZ234883A (en) 1989-08-22 1995-01-27 Merck Frosst Canada Inc Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US5115098A (en) 1990-02-28 1992-05-19 President And Fellows Of Harvard College End-blocked peptides inhibiting binding capacity of gp120
JPH04211648A (en) 1990-07-27 1992-08-03 Nippon Kayaku Co Ltd Keto-acid amide derivative
DE4015255A1 (en) 1990-05-12 1991-11-14 Hoechst Ag OXALYL-AMINOSA-E-LEED DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICAMENT FOR INHIBITING THE PROLYL HYDROXYLASE
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
JPH06500561A (en) 1990-08-24 1994-01-20 ジ・アップジョン・カンパニー Aminopolyol-containing peptides as transition state mimetics
WO1992004370A1 (en) 1990-08-29 1992-03-19 Vertex Pharmaceuticals Incorporated Modified di- and tripeptidyl immunosuppressive compounds
GB2247456A (en) 1990-09-03 1992-03-04 Fujisawa Pharmaceutical Co Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
JPH04149166A (en) 1990-10-12 1992-05-22 Nippon Kayaku Co Ltd Novel keto acid amide derivative
AU1677092A (en) 1991-03-20 1992-10-21 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
IT1245712B (en) 1991-04-09 1994-10-14 Boehringer Mannheim Italia USEFUL HETEROCYCLIC AMINES THERAPY OF ASTHMA AND AIRWAY INFLAMMATION
US5147877A (en) 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
JPH06510902A (en) 1991-05-08 1994-12-08 バーテックス ファーマシューティカルズ インコーポレイテッド RFKBP: Novel prolyl isomerase and rapamycin/FK506 binding protein
DE69229782T2 (en) 1991-05-09 2000-04-27 Vertex Pharma NEW IMMUNE SUPPRESSIVE CONNECTIONS
MX9202466A (en) 1991-05-24 1994-06-30 Vertex Pharma NOVELTY IMMUNOSUPPRESSIVE COMPOUNDS.
JPH05178824A (en) 1991-08-05 1993-07-20 Takeda Chem Ind Ltd Asparagine derivative and its use
ZA927782B (en) 1991-10-11 1993-04-28 Ciba Geigy Novel herbicides.
WO1993007269A1 (en) 1991-10-11 1993-04-15 Vertex Pharmaceuticals Incorporated ISOLATION OF AN Mr 52,000 FK506 BINDING PROTEIN AND MOLECULAR CLONING OF A CORRESPONDING HUMAN cDNA
AU3278293A (en) 1991-12-20 1993-07-28 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
CA2091194A1 (en) * 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
WO1993023548A2 (en) 1992-05-20 1993-11-25 Vertex Pharmaceuticals Incorporated METHOD OF DETECTING TISSUE-SPECIFIC FK506 BINDING PROTEIN MESSENGER RNAs AND USES THEREOF
IT1254373B (en) 1992-05-29 1995-09-14 HETEROPROSTANOIDS, PROCEDURE FOR THEIR PREPARATION AND THEIR EMPLOYE THERAPEUTIC.
US5334719A (en) 1992-06-17 1994-08-02 Merck Frosst Canada, Inc. Bicyclic(azaaromatic)indoles as inhibitors of leukotriene bisynthesis
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (en) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
AU5748194A (en) 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5252579A (en) 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5631017A (en) 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5319098A (en) 1993-05-18 1994-06-07 Celgene Corporation Process for the stereoselective preparation of L-alanyl-L-proline
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
IT1270882B (en) 1993-10-05 1997-05-13 Isagro Srl FUNGICIDE-BASED OLIGOPEPTIDES
ATE177420T1 (en) 1993-11-04 1999-03-15 Abbott Lab CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYL TRANSFERASE
DE69512220T2 (en) 1994-03-07 2000-03-16 Vertex Pharma SULPHONAMIDE DERIVATIVES AS ASPARTYL PROTEASE INHIBITORS
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5856116A (en) 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5488816A (en) 1994-07-21 1996-02-06 Boehringer Mannheim Corporation Method and apparatus for manufacturing a coagulation assay device in a continuous manner
DE69534300T2 (en) 1994-08-18 2006-05-18 Ariad Gene Therapeutics, Inc., Cambridge NEW MULTIMERIZING REAGENT
IL115685A (en) 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5543423A (en) 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
US5621108A (en) 1994-12-05 1997-04-15 Trustees Of The University Of Pennsylvania Processes and intermediates for preparing macrocycles
US5691372A (en) 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5726184A (en) 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5614547A (en) 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5801197A (en) 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5786378A (en) 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5801187A (en) 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
JP4274584B2 (en) 1996-12-06 2009-06-10 バーテックス ファーマシューティカルズ インコーポレイテッド Inhibitor of interleukin-1β converting enzyme
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
US5945441A (en) 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
TR200001603T2 (en) 1997-12-05 2000-10-23 Astrazeneca Uk Limited New compounds

Also Published As

Publication number Publication date
EP1115703A1 (en) 2001-07-18
HUP0103565A3 (en) 2002-02-28
CN1323294A (en) 2001-11-21
US6462072B1 (en) 2002-10-08
HUP0103565A2 (en) 2002-01-28
WO2000017161A1 (en) 2000-03-30
KR20010089253A (en) 2001-09-29
JP2002526474A (en) 2002-08-20
ZA200101934B (en) 2002-09-18
AU6390599A (en) 2000-04-10
IL141552A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
AU732194C (en) Heterocyclic esters and amides
US5786378A (en) Heterocyclic thioesters
US6054452A (en) N-oxides of heterocyclic esters, amides, thioesters, and ketones
EP0957913A1 (en) N-linked sulfonamides of heterocyclic thioesters
US5935989A (en) N-linked ureas and carbamates of heterocyclic thioesters
US6462072B1 (en) Cyclic ester or amide derivatives
AU5687999A (en) Carbamate and urea compositions and neurotrophic uses
US6121273A (en) N-linked sulfonamides of heterocyclic thioesters
US6417189B1 (en) AZA compounds, pharmaceutical compositions and methods of use
MXPA01002919A (en) Cyclic ester or amide derivatives
MXPA99007931A (en) N-oxides of heterocyclic esters, amides, thioesters, and ketones
CA2602798A1 (en) Heterocyclic thioesters and ketones

Legal Events

Date Code Title Description
FZDE Discontinued